# FC RECEPTOR EXPRESSION DURING MYELOID DIFFERENTIATION

> **NIH NIH R01** · STATE UNIVERSITY NEW YORK STONY BROOK · 1992 · $113,835

## Abstract

This research involves examining, immunologically and biochemically, the
ontogeny of the human Fc-gamma Receptor (Fc-gamma R) that binds immune
complexes.  A previously isolated, mouse monoclonal antihuman neutrophil Fc
R antibody, 3GB, and its Fab fragment inhibit the binding of soluble immune
complexes or the binding and phagocytosis of antibody-coated erythrocytes
to polymorphonuclearneutrophil leukocytes (PMN).  The antigen recognized by
3G8 is present on all peripheral blood PMN, mature cells from patients with
chronic myelogenous leukemia (CML), and 15% of lymphocytes but is not found
on peripheral blood monocytes or the human Fc Receptor-bearing cell lines
HL60 or U937.  The antigen is found on myeloid cells beyond the
metamyelocyte stage in human marrow, on leukocytes from CML patients, and
on HL-60 cells treated with dimethyl sulfoxide (DMSO) or retinoic acid.
The Fc Receptor thus appears to be a late differentiation antigen on cells
of myeloid lineage.

Density gradients will be used to purify populations of cells at different
stages of myeloid maturation from either the peripheral blood of patients
with CML or HL-60 cells treated with DMSO.  Fc receptors will be
quantitated and characterized functionally on these purified cell
populations.  Immunofluorescent techniques, a sensitive radioimmunoassay,
subcellular fractionation, and surface and biosynthetic labeling of
proteins will be used to study the localization and biosynthesis of this
plasma membrane protein during myeloid maturation in studies of isolated
CML leukocytes at different stages of development, in HL-60 cells induced
to differentiate with DMSO, and in normal mature PMN.  The role of an
internal pool of FCR in PMN will be examined as a function of the
physiological and pharmacological modulation of these cells.

These studies will provide information on normal, myeloid leukocyte
physiology and the expression of a late differentiation antigen (the
Fc-gamma R) in myeloproliferative diseases.  (CS)

## Key facts

- **NIH application ID:** 3176084
- **Project number:** 5R01CA038055-08
- **Recipient organization:** STATE UNIVERSITY NEW YORK STONY BROOK
- **SAM.gov UEI:** M746VC6XMNH9
- **Principal Investigator:** Howard B Fleit
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1992
- **Award amount:** $113,835
- **Award type:** 5
- **Project period:** 1984-08-01 → 1994-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3176084

## Citation

> US National Institutes of Health, RePORTER application 3176084, FC RECEPTOR EXPRESSION DURING MYELOID DIFFERENTIATION (5R01CA038055-08). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3176084. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*